174 reports of this reaction
0.8% of all OXYMORPHONE HYDROCHLORIDE reports
#15 most reported adverse reaction
DEVELOPMENTAL DELAY is the #15 most commonly reported adverse reaction for OXYMORPHONE HYDROCHLORIDE, manufactured by Amneal Pharmaceuticals LLC. There are 174 FDA adverse event reports linking OXYMORPHONE HYDROCHLORIDE to DEVELOPMENTAL DELAY. This represents approximately 0.8% of all 20,768 adverse event reports for this drug.
Patients taking OXYMORPHONE HYDROCHLORIDE who experience developmental delay should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVELOPMENTAL DELAY is a less commonly reported adverse event for OXYMORPHONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to developmental delay, the following adverse reactions have been reported for OXYMORPHONE HYDROCHLORIDE:
The following drugs have also been linked to developmental delay in FDA adverse event reports:
DEVELOPMENTAL DELAY has been reported as an adverse event in 174 FDA reports for OXYMORPHONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVELOPMENTAL DELAY accounts for approximately 0.8% of all adverse event reports for OXYMORPHONE HYDROCHLORIDE, making it a notable side effect.
If you experience developmental delay while taking OXYMORPHONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.